Mayo Clinic study links antioxidants to lowered follicular lymphoma risk
An exhaustive study by the Mayo Clinic involving 35,159 Iowa women aged 55-69 beginning in 1986 and continuing through 2005 examined the role of antioxidant nutrients found in fruits, vegetables and other foods in raising or lowering the risk factor for developing follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
In brief, researchers concluded that:
- Greater intake of total fruits and vegetables, yellow/orange and cruciferous vegetables, broccoli and apple juice/cider are associated with a lower NHL risk, although this was only observed for follicular lymphoma, not in DLBCL.
- No strong associations were found for other antioxidant-rich foods, including whole grains, chocolate, tea or nuts.
- And no associations were found with multivitamin use or supplemental intake of vitamins C, E, selenium, zinc, copper or manganese.
Read the PubMed abstract here.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
